From: Hensley, Rex (Rex.Hensley@59MDW.whmc.af.mil)
Date: Thu Oct 14 1999 - 17:37:04 EST
Flow Users, I am trying to provide recommendations for several flow cytometry facilities nationwide on how to "properly name" the markers used in both HIV and Leukemia/Lymphoma evaluations. I have found that there does not appear to be a consensus on what should be included in the report name. (1) CDC recommends CD#, short description (2) NCCLS Document H42-T Vol. 12 #6 recommends CD#, and trade name (3) US Consensus Recommendations on Immunophenotyping Analysis of Hematological Neoplasms recommends CD#, optional trade name, and fluorochrome (4) Flow Principles for Clinical Laboratory practices recommends the CD#. Take home is CD# is required...but what else??? How are you reporting out your results? Thanks for your help Rex Hensley rex.hensley@59mdw.whmc.af.mil
This archive was generated by hypermail 2.1.6 : Thu Jan 01 2004 - 17:37:28 EST
